Restricted
ODB Funded (injection)
EAP (10g/vial Injection)
>10%:
Dermatologic: Skin tightness (IM: ≤5% to ≤17%; local)
Local: Induration at injection site (≤5% to ≤17%; incidence higher with IM), warm sensation at injection site (IM: ≤5% to ≤17%)
1% to 10%:
Dermatologic: Skin rash (2%)
Gastrointestinal: Diarrhea (3%)
Hematologic & oncologic: Eosinophilia (6%), leukopenia (2%), thrombocythemia (5%)
Hepatic: Increased serum transaminases (3%)
Local: Pain at injection site (≤1%), tenderness at injection site (≤1%)
Renal: Increased blood urea nitrogen (1%)
CBC with differential, platelet count, PT, renal and hepatic function tests periodically; number and type of stools/day for diarrhea; observe for signs and symptoms of anaphylaxis
Calcium containing IV solutions bind to ceftriaxone forming an insoluble precipitate - avoid concurrent use with calcium contaning colutions in neonates
For meningitis, administration of dexamethasone prior to first dose of ceftriaxone may be considered
Fatal cases of ceftriaxone-calcium precipitation have been reported